BTAI
BioXcel Therapeutics, Inc.Healthcare · $2M market cap
Verdict
We can't put a fair value on BTAI right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow BTAI
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds BTAI. In Q2 2026, 1 added. Who we track
Moves in Q2 2026
Added: Howard Marks
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Sep 4, 2026. How the Payback Price works